Blueprint Medicines
BPMC
BPMC was delisted on the 17th of July, 2025.
219 hedge funds and large institutions have $3.78B invested in Blueprint Medicines in 2019 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 87 increasing their positions, 56 reducing their positions, and 29 closing their positions.
209% more call options, than puts
Call options by funds: $90.8M | Put options by funds: $29.4M
55% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 56
3.21% more ownership
Funds ownership: 101.52% → 104.73% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
0% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 29
0% less funds holding
Funds holding: 220 → 219 (-1)
19% less capital invested
Capital invested by funds: $4.68B → $3.78B (-$898M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Cadian Capital Management
New York
|
+$77.4M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$21.7M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
+$20.3M |
| 4 |
HM
HealthCor Management
New York
|
+$19.6M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$18.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$28.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$24.3M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$21.1M |
| 4 |
AG
Artal Group
Luxembourg
|
-$13M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.3M |
BPMC Hedge Fund Activity: Q3 2019 in Review
219 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Blueprint Medicines (BPMC) for Q3 2019, worth a combined $3.78B — down 19% from $4.68B a quarter earlier.
Fund positioning in BPMC was balanced in Q3 2019: 29 funds opened new positions, 29 closed out, 87 added to existing stakes and 56 trimmed.
The largest buyer was Cadian Capital Management, adding an estimated $77.4M. The largest seller was Perceptive Advisors, cutting an estimated $28.5M.
- 219 institutional investors held Blueprint Medicines (BPMC) as of Q3 2019, down from 220 in Q2 2019.
- Funds reported $3.78B of Blueprint Medicines stock for Q3 2019, down 19% quarter-over-quarter.
- 29 funds opened new Blueprint Medicines positions in Q3 2019 and 29 closed out, a net change of 0 holders.
- The largest Blueprint Medicines buyer in Q3 2019 was Cadian Capital Management, an estimated $77.4M added.
- The largest Blueprint Medicines seller in Q3 2019 was Perceptive Advisors, an estimated $28.5M sold.
Based on aggregated 13F filings for Q3 2019.